19 results about "Oral application" patented technology

A bag having a bag casing made of a water-permeable and / or water vapor-permeable nonwoven and a filling material arranged therein for oral application or other application with controlled release of active substances, wherein the nonwoven contains a mixture of thermoplastic binder fibers, which are thermally activated by the action of heat and pressure, and hydrophilic, preferably cellulosic, fibers, which are not thermally activated by the action of heat and pressure, said mixture being thermally consolidated under full-area action of heat and pressure, and at least two overlapping edges of the nonwoven are connected to one another by a heat-sealed seam.

Provided is a glucuronidase activator containing, as an active ingredient, Levilactobacillus brevis (Levilactobacillusbrevis) strain I-3141 (accession number: CECT 7480).

The utility model belongs to the technical field of auxiliary devices, and particularly relates to an auxiliary device for visually impaired people to perceive colors in multiple dimensions, which comprises a book body, each page of the book body is respectively provided with a color marking card, a description card, an olfaction module and a touch module, different colors are marked on each page of the color marking card, and each page of the book body is provided with an olfaction module and a touch module. According to the braille learning book, visual impaired children can conveniently touch and read the braille learning book, the color marking cards and the touch module are fixedly connected with the book body through hook-and-loop fasteners, and shifting sense intercommunication is generated between various feelings and vision through the touch module and the olfaction module, so that things can be deeply known from multiple angles, and the visual impaired children can conveniently read the braille learning book. The visual impaired children can perceive colors in a more vivid and multi-dimensional mode, the feeling of the colors is deepened, description of the colors is more understood, and a certain foundation is laid for spoken language application and writing in the future.

The invention discloses bifidobacterium breve CCFM1505 capable of regulating skin ceramide de novo synthesis and improving skin health and a metagen thereof, and belongs to the technical field of microorganisms and medicines. The bifidobacterium breve CCFM1505 obtained through screening shows the effect of remarkably promoting skin ceramide synthesis in the aspects of external use and oral administration. The viable bacteria of the bifidobacterium breve CCFM1505 and the metabiotics thereof, especially the thallus lysate of the bifidobacterium breve, are orally taken, so that the content of ceramide in the skin tissue is remarkably increased, and meanwhile, the effects of increasing of transpedermis water loss, reducing of the water content of cuticle and inflammatory response caused by skin injury and reducing of the ceramide content can be effectively regulated and controlled, and the skin healing effect is improved. Therefore, the skin health is improved. Therefore, the bifidobacterium breve has a huge application prospect in preparation of external or oral medicines for promoting synthesis of skin ceramide and improving skin health, as well as in preparation of foods, health-care products or cosmetics.

A powdered composition for oral application of therapeutic agents includes a base material, at least one therapeutic agent, and a crosslinker. The composition is formed as a homogenous powder. An application device is also disclosed.

A glucuronidase activator including an active ingredient that is a Levilactobacillus brevis strain I-3141 deposited under accession number CECT 7480.

The invention provides an antibacterial peptide as well as application, a product and a preparation method thereof, and relates to the technical field of biology. The invention screens out a novel antibacterial peptide from kidney beans, which can specifically kill escherichia coli O157: H7 without damaging intestinal flora. By designing protective peptide chains at two ends of an effective sequence, an innovative strategy for keeping oral activity without embedding is established, and the stability and the utilization efficiency are remarkably improved. Meanwhile, a plant-based transgenic expression system is constructed, high-purity production of the antibacterial peptide is realized, and the antibacterial peptide can be directly applied to oral administration.